HUTCHMED (China) Limited (AIM:HCM)

Market Cap	1.97B
Revenue (ttm)	439.54M
Net Income (ttm)	340.78M
Shares Out	859.34M
EPS (ttm)	0.39
PE Ratio	5.92
Forward PE	13.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,937
Average Volume	36,484
Open	234.00
Previous Close	228.00
Day's Range	222.00 - 234.00
52-Week Range	185.50 - 336.00
Beta	0.48
RSI	47.74
Earnings Date	Nov 13, 2025

About HUTCHMED (China)

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 1,811
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: HCM

Financial Performance

In 2024, HUTCHMED (China)'s revenue was $630.20 million, a decrease of -24.80% compared to the previous year's $838.00 million. Earnings were $37.73 million, a decrease of -62.56%.

Financial numbers in USD